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Abstract
Rituximab is an effective immunotherapy for CD20-positive B-cell non-Hodgkin’s lymphoma. However, some
patients show resistance, particularly those suffering from more aggressive lymphoma types, such as Burkitt’s
lymphoma. Hence, Rituximab is commonly combined with several chemotherapeutic drugs. With a view to
reduce the number of such drugs, we examined the effect of combining Rituximab individually with hy-
droxyurea, vincristine, or etoposide on the killing of Ramos Burkitt lymphoma cell line type I. Cell death was
examined by using Annexin-V/propidium iodide staining. Combining Rituximab with hydroxyurea or vin-
cristine resulted in a synergistic effect, whereas combining it with etoposide resulted in a subadditive effect. In
single treatments, the percentage of cell death ranged from 23% (Rituximab) to 36% (hydroxyurea). Combining
Rituximab with hydroxyurea or vincristine resulted in a synergistic effect (83% and 74% killing, respectively). In
contrast, only a subadditive effect was noticed with etoposide (36%). We conclude that the synergistic effect of
Rituximab with hydroxyurea or vincristine is worthy of further study, and that further in vitro screening of
chemotherapeutics might identify chemo-immunotherapeutic combinations that are effective in vivo but less
toxic than currently used regimens.
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Introduction
Rituximab is highly effective in treating a wide range oflymphoproliferative disorders, including many B-cell
lymphomas (reviewed in Plosker and Figgitt1). Nevertheless,
some patients with indolent follicular B cell lymphoma re-
lapse repeatedly, and the response rate is still lower in patients
with more aggressive types of B-cell non-Hodgkin’s lym-
phoma (NHL).2,3 Rituximab is also combined with chemo-
therapy to improve long-term outcome. One of the most
commonly used immune-chemotherapeutic combinations is
R-CHOP, which combines Rituximab with cyclophospha-
mide, doxorubicin, vincristine, and prednisone.4 R-CHOP
shows a 95% response rate in indolent lymphomas5 and 94%
in aggressive lymphomas.6 However, some types of lym-
phoma, such as Burkitt’s lymphoma, require even more in-
tense chemotherapeutic treatment.
Although the introduction of chemo-immunotherapeutic
combinations has improved the outcome of NHL patients,
some individuals do not respond to treatment and relapses
remain common. Therefore, new effective strategies for NHL
therapy are needed. The strategies should aim at using as
few chemotherapeutic agents with Rituximab as possible to
reduce cytotoxicity while inducing a highly effective syner-
gistic effect. We compared the effects of separately combin-
ing three different antitumor compounds with Rituximab on
the cell death of a Burkitt’s lymphoma cell line. These com-
pounds are commonly used in therapy and research and
have different mechanisms of action: hydroxyurea, a com-
petitive inhibitor of ribonucleotide reductase7; vincristine, a
vinca alkaloid that inhibits the formation of mitotic spindles8;
and etoposide, a potent inhibitor of topoisomerase II.9 We
intended to observe whether the chemotherapeutics would
act synergistically or additively with Rituximab.
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Materials and Methods
Antibodies and reagents
Rituximab (MabThera; Roche Diagnostics; stock solution
10 mg/mL) was a kind gift from the National Oncology
Institute (Sabratah, Libya). Unless stated otherwise, all
other reagents were purchased from Sigma Chemical
Company.
Cell lines
CD20-expressing human Burkitt’s lymphoma cell line
(Ramos) was purchased from the European Collection of
Cell Culture (ECACC) (Wiltshire SP4 0JK, UK) and main-
tained in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, 200 mM L-glutamine solution
that was sterile filtered and cell culture tested, and penicillin-
streptomycin that was sterile filtered and cell culture tested.
The cells were incubated at 37C in 5% CO2. Viability was
estimated by trypan blue exclusion, and cells were used only
if their viability exceeded 90%.
Cell treatments and Annexin-V-based cell death analysis
Cells were cultured at 1· 105 cells/mL in 25-cm2 tissue
culture plates and treated with 10lg/mL Rituximab, either
alone or in combination with 1 mM hydroxyurea, 2lM vin-
cristine, or 10lM etoposide for 24 or 48 hours. They were then
washed in phosphate-buffered saline and resuspended in
binding buffer containing 0.25lg/mL Annexin-V and 5lg/
mL propidium iodide (PI; BD Biosciences) and incubated
in the dark for 15 min at room temperature before analy-
sis. Single-cell suspensions were prepared for cytometric
analysis.
Flow cytometry analysis
Calibration, parameter optimization, and compensation
for the overlap between the different fluorochrome spectra
FIG. 1. Representative of flow cytometry
plots of Ramos cell death induced by ritux-
imab or chemotherapy agents; FL1 (Annexin-
V) versus FL2 (PI) after 48 h of treatment.
Rituximab 10lg/mL; hydroxyurea 1 mM;
vincristine 2lM; etoposide 10lM. Annexin-
V +ve/PI- ve (early apoptotic cells) are those
in the lower right quadrant, whereas
Annexin-V +ve/PI+ ve (late apoptotic/ne-
crotic cells) are in the upper right quadrant.
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were obtained automatically using FacsComp software
(Becton Dickinson). Analysis and calculations were per-
formed using CellQuest (Becton Dickinson). A minimum of
20,000 events were collected.
Statistical analysis
All values are given as the mean – standard deviation
(SD). One-sample t-test was used to compare the effect of
combined treatment with the mathematical sum of the cor-
responding individual treatments.
Results
Three chemotherapeutics were evaluated for their ability
to synergize with Rituximab in the induction of cell death in
the Ramos B-cell line. For all treatments, as the time of in-
cubation increased (24 and 48 hours) more cells became
positive for both Annexin-V and PI (results not shown).
Figure 1 shows representative plots of flow cytometric
analysis of cell death.
Percentages of total apoptosis after 48 hours of incubation
are shown in Figure 2. Rituximab alone induced
23.5% – 0.74% (SD) apoptosis. Etoposide alone induced
29.8% – 0.61%, vincristine 34.6% – 1.92%, and hydroxyurea
36.1% – 0.35%. The effect of the Rituximab–etoposide com-
bination was subadditive (36.2% – 0.52%). However, hy-
droxyurea and vincristine synergized significantly with
Rituximab to induce 83.0% – 0.49% and 74.4% – 0.10% apo-
ptosis, respectively (both P < 0.001 compared to mathemati-
cal sum of individual treatments).
Discussion
In the treatment of B-cell NHLs, Rituximab alone induces
apoptosis only in a subpopulation of cells, whereas the rest
continue to proliferate. According to the literature, Ritux-
imab is effective against indolent NHL but not against ag-
gressive types.3 For that reason, standard chemotherapeutic
agents are used to increase the efficacy of treatment. One of
the most widely used combinations is R-CHOP, in which
Rituximab is combined with cyclophosphamide, doxorubi-
cin, vincristine, and prednisone. But in the absence of con-
vincing in vitro evidence, most clinical trials have often taken
an experimental approach with a broad range of combina-
tions. Systematic in vitro studies might identify simpler
immune-chemotherapeutic combinations that are as effective
as current combinations but are less toxic.
Burkitt’s lymphoma is highly aggressive, and up to eight
different chemotherapeutic drugs, alone or with Rituximab,
may be used in its treatment. The Ramos cell line was de-
rived from a human Burkitt’s lymphoma and is hence rep-
resentative of this type of neoplasm. In vitro, monomeric
Rituximab induces only modest cell death in Ramos cells.10,11
In vivo, a recent retrospective study reported that the inten-
sive chemotherapy regimens used for adult Burkitt’s lym-
phoma were associated with a favorable outcome, but the
contribution of Rituximab in combined therapy was un-
certain and the authors suggested that it warrants further
investigation.11
We evaluated the effect of combining Rituximab individ-
ually with three different chemotherapeutic drugs commonly
used in therapy and research and looked for additive or
synergistic effects. We selected these drugs because they
have distinct mechanisms of action. Hydroxyurea reduces
the proliferative capacity of cells and induces senescence-like
changes, and eventually causes cells to arrest at G1.12–15
Etoposide in vitro arrests Burkitt’s lymphoma cell lines14 and
other cells15 in S/G2 by blocking DNA replication. In con-
trast, vincristine disrupts cellular microtubules and prevents
the formation of a functional spindle, resulting in the accu-
mulation of cells in the mitotic phase.8
In vitro, pretreatment of a B lymphoma line with Ritux-
imab sensitizes them to cytotoxic drugs,16 and some clinical
trials have shown that pretreatment with Rituximab before
each chemotherapy results in an additive effect.5 However,
improved effects have also been achieved in vitro by simul-
taneous application of Rituximab and chemotherapeutic
agents.10 We observed synergistic effects when CD20-expressing
FIG. 2. Percent total cell death induced in
Ramos Burkitt’s lymphoma B cell line by
Rituximab, hydroxyurea, vincristine, etopo-
side, and combinations thereof. Cells were
incubated for 48 hours with various treat-
ments: Rituximab 10lg/mL, hydroxyurea
1 mM, vincristine 2lM, and etoposide 10lM.
‘‘Sum’’ refers to the mathematical sum of
individual treatments. Values are means
(n = 3) and error bars are standard deviations.
Asterisks: effect of combined treatment is
significantly higher ( p< 0.001) than mathe-
matical sum of corresponding individual
effects.
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human Burkitt’s lymphoma cells (Ramos) were incubated
simultaneously with Rituximab in combination with either
vincristine or hydroxyurea. This synergy seems to be in-
dependent of the mode of action of the chemotherapeutic
agents, as vincristine and hydroxyurea have different
mechanisms of action. This finding might have clinical rele-
vance, particularly in cases of Burkitt’s lymphoma, where
Rituximab is not significantly associated with improved
overall survival. It is worthwhile to evaluate the effect of
combining Rituximab individually with other chemothera-
peutics, and depending on the results, it can also be tested
with pairs of chemotherapeutics. We conclude that in vitro
studies could lay the ground for developing immuno-
chemotherapeutic treatments with fewer agents than cur-
rently used treatments and hence with fewer side-effects.
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